InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
December 18, 2024

InvestorNewsBreaks – Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, is spotlighted today in a Rodman & Renshaw, LLC report that initiated coverage with a buy rating and a price target of $12.00 per share. Based in New York City, Rodman & Renshaw is a full-service investment bank with a heritage spanning over 70 years.

In the 40+ page report, Rodman & Renshaw provides an in-depth analysis of Kairos Pharma’s innovative approaches to combating cancer drug resistance, highlighting the company’s proprietary technology and targeted therapies. The report emphasizes the company’s focus on addressing two major challenges in oncology—drug therapy resistance and immune suppression. Rodman & Renshaw notes the company’s promising advancements, including small molecules targeting immune checkpoints and T cell therapies designed to fight cancer stem cells.

To view the full analyst report, visit: https://ibn.fm/iV8fp

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit the company’s website at KairosPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).